Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2

Autor:	Monk, Bradley J., Poveda, Andrés, Vergote, Ignace, Raspagliesi, Francesco, Fujiwara, Keiichi, Bae, Duk-Soo, Oaknin, Ana, Ray-Coquard, Isabelle, Provencher, Diane M., Karlan, Beth Y., Lhommé, Catherine, Richardson, Gary, Rincón, Dolores Gallardo, Coleman, Robert L., Marth, Christian, Brize, Arija, Fabbro, Michel, Redondo, Andrés, Bamias, Aristotelis, Ma, Haijun, Vogl, Florian D., Bach, Bruce A., Oza, Amit M.
Zdroj:	In Gynecologic Oncology October 2016 143(1):27-34
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect